New research presented at the European Association of Urology Congress in London shows that prostate cancer screening using PSA blood tests and MRI scans is just as effective at identifying significant cancers and reducing deaths as established breast cancer screening programs. This finding challenges the long-standing medical consensus that has kept prostate cancer screening out of mainstream clinical guidelines for decades .

Why Has Prostate Cancer Screening Lagged Behind Breast Cancer Screening?

For over 30 years, organized breast cancer screening programs have been standard across Europe. Prostate cancer screening, by contrast, has remained largely informal and inconsistent. The main reason: doctors worried that PSA (prostate-specific antigen) blood tests were unreliable and led to overdiagnosis of cancers that would never harm patients .

Many men still undergo what's called "opportunistic" screening, meaning they get tested based on their own request rather than through a coordinated public health program. This patchwork approach means some men get screened multiple times while others never get tested at all .

What Did the New Research Actually Find?

Researchers from the German Cancer Research Centre in Heidelberg compared data from 39,392 men who received PSA testing as part of the PROBASE prostate cancer screening trial at ages 45 or 50 with data from over 2.8 million women aged 50 to 69 who participated in Germany's national breast cancer screening program using mammography .

The results revealed striking similarities between the two screening approaches when it comes to detecting clinically significant cancers. Here's what the numbers showed :

• Invasive Cancer Detection: Prostate screening identified invasive cancers in 60 to 74 percent of cases, compared to 73 percent for breast screening, showing nearly identical effectiveness at catching serious disease.
• Biopsy Rates: Similar proportions of men and women were referred for biopsy (0.8 to 2.4 percent for men versus 1.1 percent for women), because men in the PROBASE trial were pre-screened using risk stratification to determine who truly needed a biopsy.
• Unnecessary Biopsies: When biopsies were performed, prostate screening was far more likely to find significant cancer (50 to 68 percent) compared to breast screening (10 percent), meaning fewer men underwent unnecessary procedures.
• False Positives: PSA testing followed by MRI did produce more false positives than mammography (37 to 42 percent versus 10 percent), but this was offset by the superior accuracy of biopsies when performed.

How Does Active Surveillance Change the Overdiagnosis Problem?

One concern with prostate cancer screening has always been overtreatment. Prostate cancer screening identified slightly more non-aggressive cancers than breast screening (26 to 31 percent versus 22 percent). However, the researchers noted that prostate cancer has a well-established solution to this problem: active surveillance .

Active surveillance means doctors monitor lower-grade cancers with regular testing rather than immediately recommending surgery or radiation therapy. Treatment only begins if the cancer shows signs of progression. This approach significantly reduces the risk of unnecessary treatment while still catching dangerous cancers early .

Steps to Understanding Prostate Cancer Screening Options

• Get Your PSA Level Checked: A simple blood test measures prostate-specific antigen levels. If your PSA is elevated (typically 3 ng/mL or higher), your doctor may recommend further testing rather than immediate biopsy.
• Discuss MRI Imaging with Your Doctor: If PSA levels are concerning, an MRI scan can help identify suspicious areas in the prostate before a biopsy is considered, reducing unnecessary procedures.
• Learn About Risk Stratification: Ask your doctor to assess your individual risk factors, including age, family history, and PSA trends, to determine whether screening and follow-up testing are appropriate for you.
• Consider Active Surveillance if Diagnosed: If a low-grade prostate cancer is found, discuss whether monitoring with regular PSA tests and imaging might be appropriate instead of immediate treatment.

Dr. Sigrid Carlsson, who leads Clinical Epidemiology of Early Cancer Detection at the German Cancer Research Centre, emphasized the broader implications of the findings. "Until we have a population-based screening programme for prostate cancer, we can't make an exact like-for-like comparison with breast cancer," she stated. "But we can make some informed assumptions based on the data from our trial, which shows that if prostate cancer screening were extended to the wider population, then the outcomes are likely to be very similar to breast cancer" .

"There is much that prostate cancer screening can learn from breast cancer screening and that is why this analysis is an important addition to our knowledge base. The clear overall similarities between the outcomes for breast and prostate cancer screening show that we are moving in the right direction, ensuring prostate cancer screening offers more benefits than harm," said Tobias Nordstrom, a clinical urologist and Associate Professor at the Karolinska Institute in Sweden.

Tobias Nordstrom, Clinical Urologist and Associate Professor at the Karolinska Institute

What Does This Mean for Clinical Guidelines Going Forward?

The researchers argue that it's no longer logically consistent to endorse breast cancer screening while rejecting prostate cancer screening, given that the two approaches now show comparable effectiveness . However, they also urge caution, noting that their analysis compares a clinical trial with an established population-based program, which introduces some limitations .

The next critical question, according to researchers, is cost. Dr. Carlsson noted that "the final question we now need to answer is: what will this cost compared to what we are already paying for opportunistic screening? And that work is already underway" .

Dr. Carlsson

Prostate cancer kills approximately 360,000 men worldwide every year, making it one of the leading causes of cancer death in men . If these findings lead to organized, population-based prostate cancer screening programs similar to those for breast cancer, the potential impact on male mortality could be substantial. The research was presented at the European Association of Urology Congress in March 2026 and has been accepted for publication in the journal European Urology .